Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Coronary vein

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    35 result(s) found for: Coronary vein. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2021-002343-30 Sponsor Protocol Number: NEWTON-CABG Start Date*: 2021-09-21
    Sponsor Name:Unity Health Toronto, at its St. Michael’s site
    Full Title: A randomized trial of evolocumab on saphenous vein graft patency following coronary artery bypass surgery (NEWTON-CABG)
    Medical condition: Patency of graft after coronary bypass graft surgery in patients with hyprelipidaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10011079 Coronary artery disease NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023552-90 Sponsor Protocol Number: BQ123CPBP2010 Start Date*: 2011-05-05
    Sponsor Name:Medizinische Universität Wien, Abteilung für Herzchirurgie
    Full Title: Short-term endothelin A receptor blockade in patients with on-pump coronary artery bypass grafting
    Medical condition: aorto-coronary bypass surgery in patients with coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10011077 Coronary artery bypass LLT
    12.1 10011085 Ischaemic coronary artery disorders HLT
    12.1 10011090 Coronary artery surgery LLT
    12.1 10011098 Coronary bypass LLT
    12.1 10049887 Coronary revascularisation LLT
    12.1 10054366 Coronary revascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004214-16 Sponsor Protocol Number: FS014 Start Date*: 2005-01-19
    Sponsor Name:Committee of Management, Common Services Agency T/A Scottish National Blood Transfusion Service
    Full Title: A randomised control clinical study to determine whether SNBTS Fibrin Sealant promotes wound healing in patients undergoing cardiac surgery.
    Medical condition: In patients undergoing cardiac surgery the saphenous leg vein is used to replace veins used in coronary artery bypass grafts (CABG) surgery.
    Disease: Version SOC Term Classification Code Term Level
    7.1 10006894 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005600-19 Sponsor Protocol Number: APHP200072 Start Date*: 2022-06-17
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Full Title: LEvOsimendaN vs. Placebo Before Tricuspid VAlve Surgery in Patients with Right Ventricular Dysfunction
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10068176 Coronary artery bypass graft LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023839-42 Sponsor Protocol Number: H8O-CY-O027 Start Date*: 2011-04-29
    Sponsor Name:General University Hospital in Prague
    Full Title: EXEnatide in patients undergoing Coronary artery bypass grafting for improved glUcose conTrol and hemodynamIc ValuEs
    Medical condition: Patients with elective coronary artery bypass grafting with LV systolic dysfunction (EF LV ≤ 50%)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10011077 Coronary artery bypass PT
    14.1 10014698 - Endocrine disorders 10012602 Diabetes mellitus (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002142-50 Sponsor Protocol Number: POPCABG03 Start Date*: 2019-04-09
    Sponsor Name:St. Antonius Hospital
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Trial Investigating The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery.
    Medical condition: Coronary artery bypass grafting surgery with the use of one or more saphenous vein grafts.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024485-21 Sponsor Protocol Number: daisy Start Date*: 2013-04-15
    Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO
    Full Title: Dipyridamole versus Adenosine infusion in the physiologic assessment of Intermediate coronary Stenoses in the cardiac catheterization laboratorY
    Medical condition: Patients with a single ≥ 50% e <75% coronary stenosis (visually extimated) at angiography, in one ore more coronary vessels).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000013-36 Sponsor Protocol Number: 49653/416 Start Date*: 2005-08-17
    Sponsor Name:Dr. Olivier F. Bertrand , Laval Hospital
    Full Title: A Multicenter Randomized Double-Blind Trial Comparing Rosiglitazone to Placebo for the Prevention of Atherosclerosis Progression after Coronary Bypass Surgery in Diabetic Patients
    Medical condition: Atherosclerosis progression in vein grafts in diabetic patients after coronary bypass surgery.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000238-16 Sponsor Protocol Number: APD791-202 Start Date*: 2021-05-07
    Sponsor Name:Arena Pharmaceuticals, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Effect on Microvascular Obstruction of Temanogrel in Subjects Undergoing Percutane...
    Medical condition: Microvascular Obstruction
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004866 10079682 Microvascular occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005960-95 Sponsor Protocol Number: 2006UK-001 Start Date*: 2006-04-26
    Sponsor Name:Enturia, Inc.
    Full Title: Prospective, randomised clinical trial to compare the efficacy of 0.5% (w/v) chlorhexidine gluconate in 70% (v/v) isopropyl alcohol with 2% (w/v) chlorhexidine gluconate in 70% (v/v) isopropyl alco...
    Medical condition: This product is a skin disinfectant and therefore is not specific for a medicinal condition. It will be used where patients require skin disinfection prior to surgery and for care of the surgical ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001069-28 Sponsor Protocol Number: D5881C00004 Start Date*: 2015-02-10
    Sponsor Name:AstraZeneca AB
    Full Title: A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)
    Medical condition: Severe persistent Hypertriglyceridemia in High Cardiovascular Risk Patients
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) EE (Completed) LT (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004220-23 Sponsor Protocol Number: VIDEAT Start Date*: 2008-09-04
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: EFFECT OF SUPPLEMENTATION WITH CHOLECALCIFEROL ON GLUCOSE AND LIPID METABOLISM, BLOOD PRESSURE, BONE MASS, QUALITY OF LIFE, CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS WITH ISCHAEMIC HEART D...
    Medical condition: ISCHAEMIC ARTERY DISEASE
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028595 Myocardial infarct LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005410-19 Sponsor Protocol Number: HH-AT-001 Start Date*: 2013-03-11
    Sponsor Name:Jessaziekenhuis Hasselt
    Full Title: Developing a Patient Model of Controlled, Radial Artery Access Site Bleeding for Deciding on Anticoagulation Reversal in Patients Treated by Systemic Anticoagulants.
    Medical condition: With the novel oral anticoagulants, including EDOXABAN-DABIGATRANRIVAROXABAN- APIXABAN, we are entering a new era of anticoagulation for atrial fibrillation (AF) (and deep vein thrombosis). Neve...
    Disease: Version SOC Term Classification Code Term Level
    15.1 10022891 - Investigations 10060319 Anticoagulation drug level therapeutic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004877-38 Sponsor Protocol Number: PREVENT-MINS Start Date*: 2021-06-18
    Sponsor Name:Uniwersytet Jagielloński - Collegium Medicum
    Full Title: Ivabradine for PREVENTion of Myocardial Injury after Noncardiac Surgery (MINS) - PREVENT-MINS Trial
    Medical condition: Myocardial Injury after Noncardiac Surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10028601 Myocardial ischemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004082-25 Sponsor Protocol Number: D5130C00137 Start Date*: 2015-03-27
    Sponsor Name:Hellenic Cardiovascular Research Society
    Full Title: A multicenter, prospective, randomized, open label, blinded endpoint, active-comparator trial to assess the MIcrovascular integrity and left ventricular function Recovery after clopidogrel or Ticag...
    Medical condition: Patients with Myocardial Infarction with ST-segment elevation (STEMI) undergoing thrombolysis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003125-39 Sponsor Protocol Number: TRI-08892 Start Date*: 2020-10-12
    Sponsor Name:Thrombosis Research Institute
    Full Title: Early thromboprophylaxis in COVID-19 (ETHIC trial): an open label, randomized phase IIIb trial of community-based prophylactic low-molecular-weight heparin (LMWH) versus standard of care (no enoxap...
    Medical condition: Confirmed diagnosis of SARS-CoV-2 with symptomatic COVID-19 infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000934-77 Sponsor Protocol Number: 4.0 Start Date*: 2018-05-11
    Sponsor Name:Medical University of Vienna
    Full Title: Target attainment of Cefazolin Continuous Infusion for Antibiotic Prophylaxis in patients undergoing CABG surgery
    Medical condition: Patients referred for CABG to the Department of Cardiac Surgery with planned isolated left mammary artery and vein/radial artery grafts preparation will be asked to participate in this trial.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001559-15 Sponsor Protocol Number: CTO#2095 Start Date*: 2022-11-11
    Sponsor Name:Ottawa Hospital Research Institute
    Full Title: StAtins for Venous Event Reduction in Patients with Venous Thromboembolism
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001975-30 Sponsor Protocol Number: BAY59-7939/17938 Start Date*: 2016-01-12
    Sponsor Name:Bayer AG
    Full Title: Global multicenter, open-label, randomized, event-driven, active-controlled study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc ...
    Medical condition: Patients with severe aortic stenosis that require Transcatheter aortic valve replacement are at risk of thrombus formation. Rivaroxaban (oral-anticoagulant) may reduce this risk, without increasing...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10002916 Aortic valve replacement PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) NO (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) SE (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) FR (Prematurely Ended) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001319-26 Sponsor Protocol Number: FJD-COVID-ESTATINAS Start Date*: 2020-05-14
    Sponsor Name:Instituto de Investigación Sanitaria Fundación Jiménez Díaz
    Full Title: Multicenter, randomized, controlled, open-label clinical trial to assess the prognostic implications of rosuvastatin treatment in patients discharged after hospitalization for COVID-19 Positive.
    Medical condition: COVID respiratory infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 17:13:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA